TEL AVIV, Israel, Dec. 2, 2015 (GLOBE NEWSWIRE) -- Cellect Biomed Ltd. (TASE:CLBD), a company specializing in the development of an innovative technology platform which enables the functional selection of stem cells, announced today that its Chief Executive Officer, Dr. Shai Yarkoni, will present at the ASH 57th Annual Meeting on December 6, 2015 in Orlando, FL.
|ASH 57th Annual Meeting|
|Date: Sunday, December 6, 2015|
|Presentation Time: 6:00 PM - 8:00 PM|
|Location: Orange County Convention Center, Hall A|
About Cellect Biomed Ltd.
Cellect is developing an innovative technology which enables the functional selection of stem cells based on their sensitivity to apoptosis. This functional-based selection is an important breakthrough in the ability to isolate stem cells from mature cells, thereby enabling a variety of stem cell therapeutic applications.
The Company is developing its first product line, unique containers for cell selection in an apoptosis-inducing microenvironment. Cellect has proved in extensive pre-clinical studies that the use of apoptosis can largely increase the stem cell concentration in samples taken from bone marrow donors, as well as umbilical cord blood. The Company's first planned commercial product is a medical kit designed for the bone marrow transplantation market, as well as other markets that require stem cell selection. The Company is positioning itself to enable future integration of its technology in the many production procedures of stem cell-based products.
This press release may contain forward-looking statements, about Cellect's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, Cellect or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by Cellect with the TASE, press releases or oral statements made by or with the approval of one of Cellect's authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Cellect's actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause Cellect's actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements, including, but not limited to, the factors summarized in Cellect's filings with the TASE. In addition, Cellect operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. Cellect does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: U.S. Investor Contact: Stephen Kilmer (647) 872-4849 email@example.comSource:Cellect Biomed